ALEXANDRIA, Va., July 30 -- United States Patent no. 12,370,207, issued on July 29, was assigned to Celator Pharmaceuticals Inc. (Palo Alto, Calif.).

"Low-intensity treatment of hematological disorders" was invented by Ronald Cheung (Palo Alto, Calif.), Stefan Faderl (Reno, Nev.) and Qi Wang (Pennington, N.J.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The invention relates to compositions and methods for treating patients with hematological proliferative disorders who are ineligible for treatment with standard intensive chemotherapy, using low intensity treatment with CPX-351, a liposomal composition of daunorubicin and cytarabine."

The patent was filed on June 3, 2021, under Application No. 17/338,561....